Deerfield Management Company, L.P. (Series C) Autolus Therapeutics PLC Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,639,000 shares of AUTL stock, worth $11.2 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
3,639,000
Previous 3,639,000
-0.0%
Holding current value
$11.2 Million
Previous $12.7 Million
4.31%
% of portfolio
0.25%
Previous 0.27%
Shares
6 transactions
Others Institutions Holding AUTL
# of Institutions
104Shares Held
163MCall Options Held
2.8KPut Options Held
13.4K-
Wellington Management Group LLP Boston, MA24.2MShares$74.6 Million0.02% of portfolio
-
Blackstone Inc New York, NY20.5MShares$63.1 Million0.35% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X018.6MShares$57.1 Million83.42% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$47 Million2.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$38 Million0.67% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $280M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...